ABSTRACT Background: Epidemiologic studies that examined whether lignans, the most important class of phytoestrogens in the Western diet, protect against breast cancer have yielded inconsistent results. Objective: In this study, we conducted meta-analyses on the association between lignans and breast cancer risk. Design: We performed a systematic MEDLINE search to identify epidemiologic studies published between 1997 and August 2009. We calculated pooled risk estimates (REs) for total lignan exposure, dietary lignan intake, enterolignan exposure, and blood or urine concentrations of enterolactone and according to menopausal and estrogen receptor (ER) status of tumors. Results: We included 21 studies (11 prospective cohort studies and 10 case-control studies) in the meta-analyses. Lignan exposure was not associated with an overall breast cancer risk (RE: 0.92; 95% CI: 0.81, 1.02; P for heterogeneity = 0.004). However, in postmenopausal women, high lignan intake was associated with a significant reduced risk of breast cancer (13 studies; RE: 0.86; 95% CI: 0.78, 0.94; P for heterogeneity = 0.32). Breast cancer risk was also inversely associated with enterolignan exposure (4 studies; RE: 0.84; 95% CI: 0.71, 0.97) but not with blood or urine enterolactone concentrations. The associations were not significantly different between ER-status subgroups (6 studies). Conclusions: High lignan exposure may be associated with a reduced breast cancer risk in postmenopausal women. Additional work is warranted to clarify the association between lignan exposure and breast cancer risk.
INTRODUCTION
Breast cancer is the most common type of cancer worldwide and the most common cause of cancer death among women (1) . Higher circulating estrogen concentrations have been associated with an increased risk of breast cancer (2) , and many of the established breast cancer risk factors are associated with exposure to endogenous or exogenous sex-steroid hormones. Phytoestrogens are plant-derived estrogen-like compounds that are able to bind to mammalian estrogen receptors (ERs) and have been postulated to have beneficial health effects (3, 4) . Phytoestrogens may modulate estrogen metabolism by exerting an inhibitory effect on aromatase and, thereby, lower the amount of circulating estrogen in the body (5, 6) . Further proposed protective mechanisms include stimulation of apoptosis, antioxidant activity and competitive binding to ER (3, (6) (7) (8) .
There are 3 main classes of phytoestrogens: isoflavones, lignans, and coumestans. According to 2 recent meta-analyses (9, 10) , consumption of soy products rich in isoflavones may be associated with a small reduction in breast cancer risk in pre-and postmenopausal women, especially in Asian populations. Plant lignans are in high concentrations in flaxseeds and sesame (11) and in appreciable concentrations in sprouts, fruits, berries, vegetables, whole grains, and green tea (12) . In Western populations with a low intake of isoflavones, phytoestrogen intake is predominantly derived from intake of plant lignans (13, 14) . Therefore, dietary intake of lignans may be more important for prevention purposes than isoflavone consumption. Lignans possess a weaker ER-binding affinity than isoflavones, but lignans also have anticarcinogenic properties (7, 15) .
There are several ways to assess lignan exposure. Long-term dietary lignan intake can be measured by dietary questionnaires. However, before being able to enter the blood circulation to exert biologic effects, plant lignans need to be metabolized by the gut microflora into the intestinal lignan metabolites (enterolignans) enterolactone and enterodiol (16) . These bioavailable metabolites can be estimated from dietary intake data by using in vitro data from incubation of foods with human feces (17) , but this assessment does not take into account interindividual variations in microbial synthesis (18) . Measurement of enterolignans in blood and urine (7, 19, 20) is considered to be more objective and precise but only reflects short-time exposure. Lignans could have a protective effect on the development of breast cancer (5, 21) , but there is no clear evidence for an inverse association between lignans and breast cancer risk (22, 23) .
Therefore, we carried out meta-analyses on epidemiologic studies addressing lignans and breast cancer risk. Lignan exposure has been addressed according to 3 different exposure measurements, including 1) dietary intake of plant lignans, 2) estimates of exposure to enterolignans (enterolactone and enterodiol), and 3) enterolactone concentrations in blood or urine. Moreover, we assessed the effect of lignan exposure on breast cancer risk according to menopausal status and the ER status of tumors.
METHODS

Literature review for meta-analyses
A systematic MEDLINE (http://www.ncbi.nlm.nih.gov/ pubmed) search was performed to identify epidemiologic studies published between 1997 and August 2009 that reported the association between lignans and breast cancer risk. We used a combination of several Medical Subject Headings (ie, breast neoplasms, phytoestrogens, lignans, diet, nutritional sciences, blood, urine, and epidemiologic studies) and also searched for related key words in all fields. In addition, cited references in retrieved articles were reviewed to identify possible additional articles that may have been missed in the search.
Eligible publications were assessed independently by 3 reviewers (KB, AKZ, and AV). Any disagreement was resolved by consensus. We documented study design, study size, characteristics of the study population, lignan-type assessed, potential confounding factors that were adjusted for, and the dietary assessment method. Relative risks or odds ratios from regression models were extracted and used for the subsequent analyses. The most fully adjusted risk estimates (REs) and CIs for the highest quantile compared with the reference quantile (the lowest quantile) from each study were used for the meta-analyses. If only continuous REs were provided or no overall REs were reported, authors of the respective publications were addressed to obtain the REs for the highest quantile compared with the lowest quantile (18, 24) . From the REs, the SE of the estimate (SEE) was directly derived as SEE = [log (95% CI, upper limit) -log (95% CI, lower limit)]/3.92 and was used in the calculation of the pooled estimates.
If REs for the whole study population (including pre-and postmenopausal women) that assessed the association between lignans and breast cancer risk were available, the estimates were used for the calculation of the pooled REs. Otherwise, when only estimates stratified by menopausal status were reported, the estimates were firstly pooled by using a fixed-effects model and included afterwards in the calculation of the pooled estimates (25) (26) (27) (28) (29) .
We initially calculated a pooled estimate for all studies. Biomarker measurements, rather than dietary intake estimates, were included when both estimates were available from one study population. Subsequently, separate analyses were performed for dietary intake and biomarker studies. Studies using either blood or urine for biomarker measurements were analyzed together because blood and urine concentrations of enterodiol and enterolactone were previously shown to correlate very well (18) . Analyses of the biomarker studies were also conducted for all women and subgroups of women according to menopausal status (overall, premenopausal, and postmenopausal) because menopausal status might modify the effects of lignans on breast cancer risk. Finally, we pooled all studies reporting separate REs by receptor status according to ER status.
Statistical methods
All analyses were carried out with the meta and rmeta packages of the statistical software environment R (version 2.7.1) (30) . The statistical analyses included a test of heterogeneity to determine whether the study results (of groups) were significantly heterogeneous. Thereby, the correct model for the combination of single-study results to a common pooled estimate could be determined. Several statistical and quantifying measurements were used to assess the heterogeneity of a set of point estimates together with the respective SEs [eg, the Q statistics (31) that yielded a (2-sided) P value and the s 2 heterogeneity estimator (32)].
Weighting was performed by the inverse-variance method (33) on the basis of 2 commonly used models: the fixed-effects model (34) and the random-effects model (32) . In the prior model, one assumes that the effects are all in the same direction and, thus, are results of a common pooled effect, whereas in the latter model, there is no assumption that the effects are similar. Thus in the random-effects model, the study results are combined in a more independent way by allowing variability within and heterogeneity between studies, respectively. Fixed-effects models were used when heterogeneity was low (P . 0.1). Otherwise, randomeffects models were used. The individual study results and combined pooled estimates were illustrated in forest plots. Analyses were conducted for all women combined, all women stratified by menopausal status, and all women stratified by ER status of their tumors. For subgroup analyses, differences between the pooled REs were determined by the Q statistic.
In addition, a sensitivity analysis was conducted to investigate publication bias of the included studies. This was visualized by using a funnel plot (35, 36) and quantified by using weighted linear regression of the effect estimate on its SEE (37) .
RESULTS
Thirty-two articles (18, 22, (24) (25) (26) (27) (28) (29) that assessed the association between lignans and breast cancer risk were identified. All studies were conducted in women from Western populations, the only exception being one study (50) on the association between urinary enterolignans and breast cancer risk in postmenopausal women from Shanghai. After excluding 4 articles (45, (59) (60) (61) on the basis of smaller subgroup analyses of their respective larger studies, one article (58) that assessed intake of phytoestrogens in adolescents, one article (53) that included women having a palpable cyst, and 2 articles (24, 46) that did not report overall plant lignan or enterolignan intake, 24 articles were included in the meta-analyses. Twenty-one of these articles were independent studies: 9 studies (25, 26, 28, 29, 38, 39, (41) (42) (43) (44) reported only on dietary intake of lignans and enterolignans, 10 studies (18, 25, 47-52, 54, 57) reported solely on biomarker measurement, and 2 studies reporting on both dietary intake and biomarker measurement assessments (22, 40, 55, 56) .
Epidemiologic studies that investigated the association of dietary lignans and calculated enterolignans with breast cancer risk in premenopausal and/or postmenopausal women are summarized in Table 1 . Of the 11 studies published, 4 studies were prospective cohort studies, and 7 studies were case-control studies. Five of these studies (26, 28, 29, (40) (41) (42) stratified their analyses by ER status of the tumor. The association between enterolignan concentrations in plasma, serum, or urine and breast cancer risk was investigated in 12 studies: 8 nested casecontrol studies within a cohort study and 4 case-control studies ( Table 2) . Nine studies (18, 45, 49, 51, 52, (54) (55) (56) (57) investigated Tables 1  and 2 . Dietary intake of lignans or calculated enterolignans was inversely associated with breast cancer risk in 9 (22, 25, 26, 28, (39) (40) (41) (42) 44) of the 11 studies (3 prospective cohort and 6 casecontrol studies). In the other studies (29, 43) , nonsignificant increased breast cancer risks with higher plant lignan intake were observed. For the separate calculation of enterolignans, 4 studies (22, 25, 28, 29, 40) showed inverse associations with breast cancer risk. Six (47, 49, 50, 54, 55, 57) of the 12 studies on enterolignan concentrations in plasma, serum, or urine showed decreased breast cancer REs, and 4 of the mentioned studies were significant (47, 49, 54, 55) . Overall, there was no significant decreased risk of breast cancer associated with the highest compared with the lowest quantiles of lignan exposure (intake or biomarker-based), with a pooled RE of 0.92 (95% CI: 0.81, 1.02) ( Figure 1, Table 3 ). There was significant heterogeneity across studies (P heterogeneity = 0.005). When subgrouping the studies by menopausal status, no association for premenopausal women was shown, but a significant inverse association for postmenopausal women was observed (pooled RE: 0.86; 95% CI: 0.78, 0.94).
Nine studies (18, 26, 28, 40, 41, 44, 48, 54, 57) also evaluated the association of lignans and enterolignans with breast cancer risk by ER status, and 7 (26, 28, 41, 44, 48, 54, 57) of these studies were in postmenopausal women. One study (22) only reported REs for ER-positive but not ER-negative tumors. Another study (48) did not report REs and only mentioned a slight change in risk when considering ER-positive tumors compared with the whole study population. High lignan exposure was not significantly associated with either ER-positive or ER-negative tumors (data not shown). In postmenopausal women, there was no indication that high lignan intakes were differently associated with ER-positive tumors (pooled RE: 0.82; 95% CI: 0.69, 0.94) and ER-negative tumors (pooled RE: 0.87; 95% CI: 0.67, 1.08) (P interaction = 0.70).
The association with breast cancer risk separately for calculated dietary plant lignans and dietary enterolignans is shown in Figure 2 . There was an inverse association between dietary plant lignans and breast cancer risk, which was not significant (pooled RE: 0.94; 95% CI: 0.82, 1.05) (Figure 2A) , and studies were significantly heterogeneous (P heterogeneity = 0.02, s 2 = 0.0159) ( Table 3) . When subgrouping the studies by menopausal status, no association for premenopausal women was shown, but a significant inverse association for postmenopausal women was observed (pooled RE: 0.86; 95% CI: 0.77, 0.94). High exposure to dietary enterolignans reduced breast cancer risk by 16% (pooled RE: 0.84; 95% CI: 0.71, 0.97 ( Figure 2B ), and there was no significant heterogeneity across studies (P heterogeneity = 0.42, s 2 = 0) ( Table 3 ). The combined breast cancer REs of studies that assessed plasma, serum, and urinary enterolactone concentrations are shown in Figure 3 . Overall, no significant association was observed; the pooled RE was 0.90 (95% CI: 0.69, 1.10), and there was significant heterogeneity between studies (P heterogeneity = 0.03, s 2 = 0.0597) ( Table 3) when the highest to the lowest quantiles of enterolactone were compared. Two biomarker measurement studies (18, 57) also showed no differential association for postmenopausal ERpositive and ER-negative tumors (P interaction = 0.98).
DISCUSSION
We conducted several meta-analyses to assess the strength of the current evidence for an effect of high lignan intake compared with low lignan intake on breast cancer risk and included 11 cohort (or nested case-control) and 10 case-control studies. Overall, no clear association between lignan exposure (dietary or biomarker assessment) and breast cancer risk was observed, and there was significant heterogeneity across studies. However, in postmenopausal women we showed a significant decreased breast cancer risk on the basis of 13 studies that showed limited heterogeneity. The inverse association did not appear to be different for ER-positive and ER-negative tumors. When differentiating by lignan-exposure measurements, this risk reduction in postmenopausal women remained significant for high dietary plantlignan intake. Although based on only 4 studies, an overall significant protective effect of high dietary enterolignan exposure was also shown. Enterolactone concentrations were not associated with a risk overall or by menopausal status.
Significant findings according to lignan-exposure measurements were recently reported (62) . Pooled REs in those metaanalyses were in the same direction but slightly different because of differences in inclusion criteria (eg, no overall effect estimation and exclusion of studies of urine measurements), and stratification by ER status was not performed (62) . These observations suggest that plant lignans confer a protective effect for breast cancer in postmenopausal women but not in premenopausal women. It is possible that the mechanism by which lignans act may be effective only at low endogenous estradiol concentrations as shown in postmenopausal women. Higher lignan concentrations were shown to be associated with higher sex hormone-binding globulin (SHBG) concentrations and higher binding of free estradiol (63, 64) . Enterolactone may reduce estrogen concentrations through the inhibition of enzymes involved in estrogen synthesis and metabolism, such as aromatase and 17 b-hydroxsteroid dehydrogenase (65, 66) .
We did not observe any difference in lignan effects according to ER status of tumors, which corroborates additional proposed mechanisms of action including the reduction of angiogenesis and stimulation of apoptosis (7, 67) . Flaxseed, the main source of dietary lignans, was shown to be able to inhibit the proliferation of ER-positive and ER-negative tumor cells (68, 69) . Thus, it is also possible that other food constituents in lignan-rich diets, for example a-linoleic acid (70), cause a protective effect (62) . Unfortunately, potential differential effects of lignan exposure on the risk of ER-positive and ER-negative breast cancer could not be fully elucidated because only a small number of studies stratified their results by ER status. More studies assessing the effect modification by ER status are needed to clarify this issue.
There are strengths and limitations to the different measures of lignan exposure. Food-frequency questionnaires assess dietary habits generally over the entire previous 6 months or longer and, thus, are able to capture the long-term situation of lignan intake. However, there are limitations leading to measurement errors that are not only due to recall bias but also to the estimation by using food-composition databases, which may not be complete for the whole range of foods consumed (39) . Measured enterolactone concentrations are expected to reflect short-term intake and were previously shown to weakly correlate with dietary intake of plant lignans (55) . However, we did not find a significant risk reduction in studies measuring enterolactone concentrations in body fluids, although 2 studies (28, 57) observed a significant reduced risk in postmenopausal women with ER-positive tumors. Biomarker measurements, which account for activity of the intestinal microflora, are considered to be more accurate and not prone to recall bias; however, measurement in a single blood or urine sample may only reflect recent dietary intake. As the gut microflora may differ by its concentration and composition from one person to the other (71), antimicrobials (ie, antibiotics) may lead to intra-and interindividual variations in amounts of intestinal lignan metabolites that are converted from consumed lignans by the gut bacteria (72) . Further, intraindividual variation within and between days (73) and interindividual variation in age, bowel movement, body mass index, and other lifestyle factors, such as smoking, may affect serum-enterolactone concentrations (15, 74, 75) . It has also been suggested that gut transit time and a diet rich in fat modulate the production of enterolignans and, thus, may contribute to interindividual variation (15, 75, 76) . However, antibiotics are regarded to have the strongest effect (15) . Enterolactone measurements may also be affected by cancer therapy after diagnosis; for example, isoflavones and lignans were both shown to affect tamoxifen action (77, 78) . Heterogeneity was shown to be significant when all studies and in some subgroups of the meta-analyses were considered. Although random-effects models were used to account for heterogeneity, this may have had an effect on the estimation of pooled effects. There are multiple possible sources of heterogeneity. Study heterogeneity in the overall estimate may have been attributable to the fact that different measurement types (dietary intakes and biomarker measurements) were combined and that the intakes between the studies varied strongly. The observation that the pooled estimates separately for the different measurement types were also significantly heterogeneous suggests that combining different measurement types may not fully explain the heterogeneity observed. Stratification by menopausal status reduced heterogeneity, particularly for the pooled estimates for postmenopausal women. If the effect of lignan exposure is truly differential by menopausal status, combining studies in pre-and postmenopausal women may have led to considerable heterogeneity in the overall effect. Generally, there was greater study heterogeneity for premenopausal women than for postmenopausal women, which, in part, might also be due to the smaller size of studies in premenopausal women.
The large differences in lignan and enterolignan concentrations between the studies may be another source of heterogeneity. Although some of this variation may be real, the use of various dietary databases may have led to differences in estimated plant-lignan intake between the studies. It is also likely that recent studies used more complete databases, so that more recent studies may have generally estimated higher plant-lignan intake than earlier studies. Some recent studies also estimated intake of the plant lignans pinoresinol, and lariciresinol in addition to secoisolariciresinol and matairesinol. Thus, our pooled estimates may have been affected by comparisons made at different amounts of plant-lignan intake. The studies also used different quantile ranges to categorize their data, which resulted in varying increments of lignan exposures between the studies. This is a drawback of our analyses and meta-analyses in general, in which estimates of different increments of quantitative exposure are used for pooling. From each study we used the estimates of the highest quantile compared with the lowest quantile of exposure because the individual intake values were not available; thus, we recognized that these increments may not be comparable because of variation in lignan exposure levels and increment levels between studies. Moreover, several studies indicated a nonlinear association between lignan exposure (22, 26-29, 38, 42, 51, 52, 54, 56, 57) and breast cancer risk, which we were not able to investigate.
Finally, general study aspects are likely to contribute to heterogeneity between the studies as well. All individual study REs were adjusted for potential but varying confounding factors, and therefore, residual confounding cannot be excluded. Several studies (38, 39, 47, 51) reported an overall number of case and control subjects without specifying the exact number of pre-and postmenopausal participants. Also, several studies (18, 22, 38, 39, 47, 51) did not analyze or report their data by menopausal status; therefore, not all studies could be included in the subgroup analysis according to menopausal status.
Publication bias can be excluded because the funnel plots were relatively symmetrical (the funnel plot for all studies is shown in Figure 4 ), and the linear regression analysis resulted in nonsignificant asymmetry of the funnel plot for all studies (P = 0.56).
Phytoestrogen-gene interactions may explain, in part, the conflicting results with respect to the effects of phytoestrogens on breast cancer risk (65) . For example, phytoestrogens may modulate sex hormone-binding globulin and sex-hormone concentrations in postmenopausal women and interact with genetic variants involved in estrogen signaling pathways. Nevertheless, not much is known in the field of lignans and genetic polymorphisms in association with breast cancer risk. Two studies (25, 61) reported that the CYP17 5#-untranslated region MspA1 genetic polymorphism modifies the association between lignan exposure and premenopausal breast cancer risk. Another recent study showed suggestive evidence for an interaction between enterolactone concentrations and one of several investigated polymorphisms in the ER a gene (79) .
The effect of phytoestrogens on breast cancer prognosis has scarcely been investigated. One study (80) observed no association between high lignan intake compared with low lignan intake in relation to breast cancer-specific mortality (hazard ratio: 0.95; 95% CI: 0.60, 1.51). Additional experimental studies in the estrogenic and nonestrogenic activities of different lignans in breast tissue may help to elucidate the biological mechanisms of phytoestrogens in modulating breast cancer risk.
In conclusion, lignans were not significantly inversely associated with overall breast cancer risk. However, we showed that high lignan exposure, particularly high plant-lignan intake, was associated with a risk reduction especially in postmenopausal women. It remains unclear whether the effect of lignans on breast cancer risk differs by ER status of the tumor. Therefore, further studies are warranted to confirm the observed protective effect of lignan exposure on postmenopausal breast cancer risk, and to assess possible genetic modifying effects that could clarify the association between exposure to lignans and breast cancer risk.
